文献速递核素与放射性配体治疗

177Lu-DOTATATE 肽受体放射性核素治疗对小肠神经内分泌肿瘤肠系膜肿块疗效的结局:MesenLuth 研究,法国内分泌肿瘤研究组与 Endocan-RENATEN 网络的全国性研究

Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network.
PubMed 文献 · J Nucl Med · 2024-02-01

该全国性研究纳入 52 例接受至少 1 疗程 177Lu-DOTATATE 肽受体放射性核素治疗(PRRT)的晚期小肠神经内分泌肿瘤(SI-NET)伴肠系膜肿块(MM,≥2 cm 且呈回缩性)患者。MM 客观缓解率(ORR)为 4%(n=2),非 MM ORR 为 8%(n=4);无患者出现 MM 代谢缓解,非 MM 代谢缓解率为 12%(n=6)。结论认为 177Lu-DOTATATE PRRT 不导致 MM 形态学缓解(ORR<5%),但可维持 MM 稳定、MM 相关副作用少,并对 MM 相关症状有 relevant 影响。

要点

  • 52 例晚期 SI-NET 伴肠系膜肿块患者接受 177Lu-DOTATATE PRRT,MM ORR 为 4%(n=2)。
  • 无患者出现 MM 代谢缓解,非 MM 代谢缓解率为 12%(n=6)。
  • 26 例基线有 MM 相关症状者中 46% 获临床缓解,4 例出现胃肠道并发症。

核心结论

  • 本研究证实 177Lu-DOTATATE PRRT 不导致肠系膜肿块形态学缓解(ORR<5%),但可维持肿块稳定、MM 相关副作用少,并对 MM 相关症状有 relevant 影响。

研究设计与样本

  • 从法国国家 Groupe d'étude des Tumeurs Endocrines 数据库识别接受至少 1 疗程 177Lu-DOTATATE PRRT 的晚期 SI-NET 伴 MM(≥2 cm 且呈回缩性)患者,共纳入 52 例。
  • 主要终点为 MM 客观缓解率(ORR)低于 5%;次要终点包括代谢缓解、MM 相关安全性、临床缓解、MM 无进展生存(PFS)及非 MM PFS。

主要发现

  • MM ORR 为 4%(n=2),非 MM ORR 为 8%(n=4)。
  • 无患者出现 MM 代谢缓解,非 MM 代谢缓解率为 12%(n=6)。
  • 26 例基线有 MM 相关症状的患者中,46% 出现临床缓解。
  • 4 例患者在 PRRT 期间出现胃肠道并发症。
  • MM 相关 PFS 中位数未达到,非 MM PFS 为 50.3 个月(95%CI 38.2–61.7 个月)。

关键数值与推荐

  • MM 客观缓解率(ORR)为 4%(n=2),低于预设的 5% 阈值。
  • 非 MM ORR 为 8%(n=4),非 MM 代谢缓解率为 12%(n=6)。
  • 26 例有基线 MM 相关症状者中 46% 达临床缓解。
  • 非 MM PFS 为 50.3 个月(95%CI 38.2–61.7 个月),MM 相关 PFS 中位数未达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has shown its efficacy in patients with progressive SI-NETs. However, because of specific tissue characteristics of desmoplastic MMs, we hypothesize that these lesions may be refractory to 177Lu-DOTATATE PRRT. Methods: From the national French Groupe d'étude des Tumeurs Endocrines database, we identified patients with an advanced SI-NET and a MM (≥2 cm with a retractile aspect) of a SI-NET treated by at least 1 course of 177Lu-DOTATATE PRRT. The primary endpoint was a MM objective response rate (ORR) of less than 5%. Secondary endpoints were metabolic response, MM-related safety, and clinical response, as well as MM progression-free survival (PFS) and non-MM PFS. Results: In total, 52 patients were included. The MM ORR was 4% (n = 2), and the non-MM ORR was 8% (n = 4). No patient had a MM metabolic response, and the non-MM metabolic response rate was 12% (n = 6). Among the 26 patients with baseline MM-related symptoms, 46% had a clinical response. Four patients presented with gastrointestinal complications during PRRT. The median MM-related PFS was not reached, and the non-MM PFS was 50.3 mo (95% CI, 38.2-61.7 mo). Conclusion: This study confirms that 177Lu-DOTATATE PRRT does not lead to morphologic response on MMs (ORR < 5%). However, it allows MM stability, with few MM-related side effects, and has a relevant impact on MM-related symptoms.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Al Mansour L, De Mestier L, Haissaguerre M, et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. J Nucl Med. 2024. PMID: 38212066. doi:10.2967/jnumed.123.266063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。